Pillar 1 - FTO (new thread), page-2942

With so many independent papers continually produced about 'CS1' I'll admit to becoming a little complacent about 'just another research paper referring to the capabilities of bisantrene'.

Time to wake up myself up.

Just how often do you see a biotech's lead asset described as 'drastically' impacting cancer cells (or similar)?

Seriously.

In fact, the question could probably be asked better....

'Just how often do you see another biotech's lead asset described as 'drastically' impacting cancer cells (or similar)....by multiple, unrelated, independent research organisations that have no commercial benefit in promoting that lead asset?'

Then consider none of them are even reporting on CPACS yet.

I truly hope that some of the $2M saving on trials will be put towards hiring a gun legal team; BP will not sign-off on $B unless their sharpest negotiation and legal minds are all over it. Grads need not apply.

I never doubted the science; the reasons why I changed sentiment from 'buy' to 'hold' had more to do with what went on outside of the lab.

I've seen enough in recent times to change sentiment from 'hold' to 'buy'. Good work @RaceOncology.